Oxford Pharmascience Group

Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take. Since Oxford Pharmascience's products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market. The Company's pipeline is focused on cardiovascular disease and pain relief indications addressing unmet patient needs with significant commercial potential in global markets. The company was founded in February'08 and floated in London's AIM market in February 2010.
Type
Public
HQ
London, GB
Founded
2008
Employees
10 (est)-9%
Oxford Pharmascience Group was founded in 2008 and is headquartered in London, GB

Oxford Pharmascience Group Locations

London, GB

Oxford Pharmascience Group Metrics

Oxford Pharmascience Group Summary

Market capitalization

$253 B

Closing share price

$0.21
Oxford Pharmascience Group's current market capitalization is $253 B.

Oxford Pharmascience Group Financials

We estimate that Oxford Pharmascience Group's revenue is £749 K in FY, 2015 which is 6.24% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£1.03 M£705 K£749 K

Revenue growth, %

-31.5%6.2%

Cost of sales

£693 K£482 K£591 K

Gross profit

£336 K£223 K£158 K

Gross profit Margin, %

32.7%31.6%21.1%

Operating expense total

£1.89 M£3.72 M£4.13 M
    We estimate that Oxford Pharmascience Group's current employees are approximately 10% female and 90% male.

    Oxford Pharmascience Group News

    Oxford Pharmascience Group Company Life

    You may also be interested in